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Abstract 
Rhinoviruses are the pathogens most often responsible for the common cold, and 
are a frequent cause of exacerbations in asthma, chronic obstructive pulmonary 
disease and cystic fibrosis. Here we report discovery of IMP-1088, a picomolar dual 
inhibitor of the human N-myristoyltransferases NMT1 and NMT2, and use it to 
demonstrate that pharmacological inhibition of host cell N-myristoylation rapidly and 
completely prevents rhinoviral replication without inducing cytotoxicity. Identification 
of cooperative binding between weak-binding fragments led to rapid inhibitor 
optimization through fragment reconstruction, structure-guided fragment linking, and 
conformational control over linker geometry. We show that inhibition of co-
translational myristoylation of a specific virus-encoded protein (VP0) by IMP-1088 
potently blocks a key step in viral capsid assembly, delivering low nanomolar 
antiviral activity against multiple rhinovirus strains, poliovirus and foot-and-mouth 
disease virus, and protection of cells against virus-induced killing, highlighting the 
potential of host myristoylation as a drug target in picornaviral infections. 
Main Text 
Rhinovirus (RV) is the pathogen most often responsible for the common cold, and is 
the most frequent cause of exacerbation and morbidity in important respiratory 
diseases including asthma, chronic obstructive pulmonary disease (COPD)1, and 
cystic fibrosis2,3. It is a member of the Picornaviridae family that includes other 
important human and animal pathogens such as poliovirus (PV), foot-and-mouth 
disease virus (FMDV), coxsackievirus, hepatitis A virus and enterovirus 71 (EV-A71). 
Despite the importance of RV as a pathogen in respiratory diseases, a specific 
treatment is lacking. On the one hand, massive RV serotypic diversity (over 100 
serotypes are known) precludes generation of broad-spectrum vaccines, whilst rapid 
3 
 
emergence of resistance has been observed for previous inhibitors targeting the 
virus itself, thanks to its rapid replication and high mutation rate4. 
The RNA genome of RV is translated by host ribosomes into a single polyprotein 
(Fig. 1a) that is processed by viral proteases to form the capsid precursor protein, 
and a number of non-structural proteins required for completion of the viral life 
cycle5. The capsid precursor is further processed into three capsid proteins VP0, 
VP3 and VP1 (Fig. 1b), triggering a cascade of protein self-assembly which 
ultimately leads to formation of infectious virions. This cascade starts with formation 
of a VP0/VP1/VP3 complex termed a protomer; five protomers assemble into 
pentamers, and twelve pentamers and the viral RNA genome then assemble to form 
an icosahedral virion6. The final maturation step involves cleavage of VP0 into VP4 
and VP2, in the intact viral capsid.  
VP0 is encoded at the N-terminus of the viral polyprotein (Fig. 1a), and in many 
picornaviruses is N-myristoylated by host cell N-myristoyltransferase (NMT). NMT 
undertakes transfer of myristate from myristoyl coenzyme A (Myr-CoA) to the N-
terminus of a range of proteins during protein translation (i.e. co-translationally), and 
is widely conserved across all eukaryotic species7, with higher organisms such as 
humans expressing two NMT proteins (NMT1 and NMT2) in most tissues. 
Mutagenesis studies in poliovirus suggest that VP0 N-myristoylation plays a role in 
capsid assembly and infectivity8-11, and host NMT may therefore be an attractive 
antiviral drug target that is minimally susceptible to both serotypic variation and the 
propensity of the virus to mutate, since host NMT is an invariant factor in viral 
replication. 
Here we report the development of a novel class of dual human NMT1/2 inhibitors 
through a fragment reconstruction and linking approach which delivers a 100,000-
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fold improvement in potency, and the first picomolar inhibitors of the human 
enzymes. We use these compounds to demonstrate that pharmacological inhibition 
of VP0 myristoylation by NMT in the host cell results in a specific failure to assemble 
virions, leading to complete suppression of RV replication and infectivity, and confirm 
the essentiality of VP0 myristoylation for RV viability through mutagenesis. We show 
that this mode of action is widely efficacious across multiple RV strains, in primary 
tissue models, against poliovirus and FMDV, and prevents virus-induced cytotoxicity 
in host cells, indicating the potential of the human NMTs as broad spectrum 
antipicornaviral drug targets.  
Results 
A fragment reconstruction and merging approach leads to a picomolar human 
NMT inhibitor  
NMT inhibitors to date, including those reported by our labs, have been developed 
primarily against NMT in protozoan parasites or fungi12, and compounds in these 
inhibitor series only modestly reduce protein N-myristoylation in human cells13. We 
reasoned that a new series optimized specifically against the human NMTs could 
deliver greatly improved cellular activity, and a tool with which to explore the anti-
rhinoviral potential of NMT inhibition. During exploration of hits from a high-
throughput screen against NMT from the human malaria parasite Plasmodium 
falciparum14, we identified a novel fragment-like compound IMP-72 (Fig. 2a) with 
weak but measurable activity against human NMT1 (HsNMT1, IC50 20 µM). The 
binding mode of this fragment was initially determined in NMT from malaria parasite 
Plasmodium vivax (PvNMT) in the presence of a non-hydrolysable myristoyl CoA 
analogue (NHM)15 (Fig. 2b; see Supplementary Fig. 1 for ligand electron density 
maps). IMP-72 was found to interact through its dimethylamine with the C-terminal 
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carboxylate of the enzyme, a residue essential for catalytic activity. However, IMP-72 
also makes a novel interaction through the phenyl ring to displace a tyrosine residue 
in the active site (Y211 in PvNMT); since this residue is conserved in human NMT 
(Y296 in HsNMT1), we considered IMP-72 a promising starting point for 
development of an inhibitor of the human enzymes.  
We noted that IMP-72 binds in a region complementary to a quinoline inhibitor 
previously reported by our labs (MRT00057965, Supplementary Fig. 1)16 and 
exploits distinct interactions, suggesting an opportunity for rapid optimization through 
fragment merging. However, on examination of the overlaid binding modes it was 
evident that the two fragments would clash unfavorably in the active site of the 
enzyme (Supplementary Fig. 1). We therefore reconstructed MRT00057965 as a 
simplified quinoline fragment (IMP-358) which we hypothesized would recapitulate 
the key interaction of MRT00057965 with a conserved serine (S319 in PvNMT, S405 
in HsNMT1) at the base of the pocket, without clashing with IMP-72. At a 
concentration of 100 µM this weakly-binding fragment showed only 17% inhibition of 
HsNMT1. However, in the presence of 100 µM IMP-358 the potency of IMP-72 was 
increased >25-fold for PvNMT (to <5 nM) and 300-fold for HsNMT1 (to 65 nM), 
suggesting a remarkable synergism between these distinct binding modes. The 
potential for cooperative binding was supported by a quaternary X-ray structure of 
PvNMT in complex with IMP-72, IMP-358 and NHM, in which the fragments adopt 
complementary binding sites (Fig. 2c and 2d). Taken together, these data suggest 
that binding of IMP-72 presents an optimal cavity for binding of IMP-358, delivering 
synergistic inhibition ideal for fragment linking. 
We next sought to replace the quinoline with a more ligand efficient motif to improve 
both solubility and potency, whilst developing a strategy to link the fragments through 
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the phenyl ring of IMP-72. An ether linker combined with a trimethylpyrazole resulted 
in a synthetically tractable route to IMP-917, a dual HsNMT1/2 inhibitor with >1000-
fold improved potency over IMP-72 (Fig. 2a). Parallel optimization of the IMP-72 
indazole core by N-methylation improved chemical stability by reducing the potential 
for elimination of dimethylamine, whilst also delivering a modest improvement in 
potency (IMP-994, Fig. 2a). Inspection of the binding mode of IMP-917 in human 
NMT1 with the co-substrate Myr-CoA (Fig. 2e) revealed that the first two atoms of 
the ether linker lie in the plane of the phenyl ring; this conformation has previously 
been proposed to be inherent to this motif17, and exerts a suboptimal interaction with 
HsNMT1. Moving the fluorine substituent on the phenyl ring to flank the linker yielded 
IMP-1031 (Fig. 3a), a single digit nM IC50 dual human NMT1/2 inhibitor; 
crystallography confirmed that the linker is forced into an out-of-plane conformation, 
optimizing the interaction with S405 (Supplementary Fig. 1). Finally, reintroduction of 
the fluorine substituent present in the original IMP-72 core resulted in IMP-1088, a 
sub-nanomolar IC50 inhibitor of human N-myristoyl transferases HsNMT1 and 
HsNMT2 (Fig. 3b). A high resolution (1.88 Å) X-ray structure with HsNMT1 and the 
cofactor myristoyl-CoA (Fig. 3b) shows that IMP-1088 forms an extensive network of 
interactions in the protein substrate pocket, supporting its unprecedented potency. 
Indeed, IMP-1088 is sufficiently potent to be beyond the sensitivity of enzyme 
inhibition assays, suggesting tight binding in the picomolar range18. The 
difluorophenyl indazole linker takes a unique trajectory through the enzyme active 
site, displacing the Y296 side chain; in this more exposed conformation the tyrosine 
ring stacks over the inhibitor, resulting in a deeply buried ligand binding mode. 
Furthermore, the ether linker is twisted out of plane as designed, enabling the 
pyrazole ring to form a strong hydrogen bond with S405, and inducing an alternative 
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conformation for H298 by comparison with IMP-917 (Supplementary Fig. 1), as well 
as stacking and hydrophobic interactions with the side chains of V181, F188, F190, 
and F311. The interactions of IMP-917 and IMP-1088 with HsNMT1 were further 
compared by surface plasmon resonance (SPR) to determine the correlation of 
binding affinity with enzyme inhibition (Supplementary Fig. 2). The measured 
equilibrium dissociation constants (KD) of 46 nM for IMP-917 and <210 pM for IMP-
1088 were in line with their respective HsNMT1 IC50 values, with the latter based on 
an upper limit for the dissociation rate constant (kd) due to the extremely slow off-rate 
of IMP-1088.  
Human NMT inhibitors inhibit rhinovirus capsid myristoylation in cells 
With an exceptionally potent inhibitor in hand we next explored the impact of IMP-
1088 on RV capsid myristoylation in cells, using a chemical proteomic approach 
which takes advantage of alkyne-tagged myristate analogue, YnMyr (Supplementary 
Fig. 3)13,19. Metabolic labeling with YnMyr over a single-cycle 6-hour synchronous 
infection with human rhinovirus strain RV-A16 in HeLa cells (multiplicity of infection 
(MOI) of 20) was followed by copper catalyzed azide-alkyne cycloaddition (CuAAC) 
of protein lysate to AzTB, an azide capture reagent bearing a TAMRA fluorophore 
and biotin dual label (Supplementary Fig. 3)19. Subsequent SDS-PAGE and in-gel 
fluorescence analysis revealed a new fluorescent band at the expected molecular 
weight of VP0 (approximately 37 kDa), superimposed on a band pattern 
characteristic of NMT-dependent labeling of N-myristoylation in HeLa cells (Fig. 
3c)13,20, suggesting that VP0 is myristoylated at 6 hours post-infection. Global 
identification of proteins for which myristoylation is selectively inhibited by IMP-1088 
was performed by quantitative chemical proteomic comparison of YnMyr-tagged 
proteins in HeLa cells infected with RV, and treated with 50 nM IMP-1088 versus 
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vehicle (DMSO) treated controls. Proteins were subjected to ligation to AzRB, an 
azide capture reagent bearing a trypsin-cleavable linker and biotin dual label 
(Supplementary Fig. 3)13,21, followed by affinity enrichment on NeutrAvidin beads, 
on-bead digestion with trypsin, nanoLC-MS/MS analysis of tryptic peptides, and data 
processing by label-free protein quantification (LFQ) in MaxQuant22,23. LFQ 
intensities across replicates were highly reproducible (R2 = 0.96-0.98, n = 3), and 
permutation-based false discovery rate (FDR) two sample t-tests were used to 
compare inhibitor-treated samples with controls. Multiple N-myristoylated proteins 
were identified in enriched samples, including the RV polyprotein which was 
significantly less enriched in the presence of IMP-1088 (Fig. 3d). Global proteome 
analysis in the same samples showed no significant changes in protein abundances 
across the whole proteome in the presence of IMP-1088, consistent with NMT 
inhibitor-dependent reduction in enrichment (Supplementary Fig. 4). Inhibition of 
capsid myristoylation was further validated by Western blot with an antibody 
recognizing rhinovirus VP0 and VP2 (Fig. 3e), whereby the amount of tagged protein 
pulled down was dose-dependently reduced by IMP-1088 while the total abundance 
of protein was unaltered. The majority of viral capsid peptides identified in the pull-
down mapped to the VP0 domain of the polyprotein, and the N-terminal YnMyr-
tagged peptide was readily identified by MS/MS (Supplementary Figs. 5 and 6). 
These data provide the first direct proteomic evidence for RV capsid myristoylation in 
human cells and demonstrate that this lipid modification is susceptible to inhibition by 
a potent NMT inhibitor. 
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NMT inhibition blocks production of infectious picornaviruses and protects 
cells from virus-induced cytotoxicity 
We next evaluated the ability of NMT inhibitors to rescue host cells from the 
cytopathic effect (CPE) caused by rhinovirus replication. HeLa cells were infected 
with RV-A16 at low MOI (0.5) for 2 days, allowing several rounds of virus replication 
in the presence of NMT inhibitor (or DMSO vehicle control), whereupon cell viability 
was measured to quantify virus-induced CPE. We compared IMP-1088 with the less 
potent analogue IMP-1031 and found that both compounds prevented virus-induced 
CPE in a dose-dependent manner (Fig. 4a), with IC50 values of 17 nM for IMP-1088 
(95% confidence interval (CI): 6.3-46 nM) and 64 nM for IMP-1031 (95% CI: 37-
114 nM), in line with their relative potencies against recombinant HsNMT. In 
contrast, IMP-994 had no effect on CPE, as expected for a weak (9 µM HsNMT1 
IC50) inhibitor (Supplementary Fig. 7). The absence of target engagement for this 
inactive control molecule in HeLa cells was further confirmed by YnMyr tagging 
experiments across a wide range of concentrations, in comparison to target 
engagement observed for IMP-1088 at low-nM concentration (Supplementary Fig. 
7). Notably, none of these compounds had any effect on cell viability measured in 
parallel in uninfected cells, under the same conditions (Fig. 4b and Supplementary 
Fig. 7). This observation is in line with previous studies showing that low cytotoxicity 
during acute NMT inhibition reflects the relatively slow turnover of human NMT 
substrates13,20, providing a substantial window between antiviral efficacy and host 
cell toxicity. The very slow off-rate of IMP-1088 may result in extended NMT 
inhibition in cells, with a potential risk of long-term cytotoxicity; however, this would 
be counteracted by recovery from inhibition through NMT re-synthesis. To test 
recovery from NMT inhibition, we treated HeLa cells with IMP-1088 for 24 h, followed 
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by wash-out of compound and measurement of in-cell NMT activity (with YnMyr) and 
cell viability 24 h later (Supplementary Fig. 8). NMT activity fully recovered by 24 h, 
and no cytotoxicity was detected at any time point, confirming the capacity of cells to 
recover from transient NMT inhibition. 
The effect of the more potent inhibitor (IMP-1088) was confirmed in a 
complementary assay measuring the titer of infectious virus produced in a single-
cycle of infection (Fig. 4c); complete suppression of new infectious virus was 
observed at 125 nM IMP-1088, with a similar IC50 to the multicycle replication assay 
(5.8 nM; 95% CI: 1.6-15 nM). The antiviral potency of IMP-1088 against RV-A16 was 
maintained against a range of different RV serotypes (Fig. 4d), and against the 
picornaviruses poliovirus and FMDV (Supplementary Fig. 9), consistent with 
inhibition of conserved and essential modification of VP0 by host NMT. Furthermore, 
IMP-1088 blocked production of infectious virus in primary human bronchial epithelial 
cells (hBEC), a model more representative of human infection (Fig. 4e), and this 
inhibition was fully maintained during co-administration of the glucocorticoid receptor 
agonist fluticasone propionate, a standard inhaled corticosteroid for patients with 
COPD and asthma (Supplementary Fig. 10)24. Remarkably, IMP-1088 significantly 
inhibited production of infectious virus even when added up to 3 hours post-infection, 
suggesting efficacy can be maintained even in the face of an active infection (Fig. 
4f). 
In addition to demonstrating the impact of NMT inhibition on infectious virus 
production, these data strongly indicate that VP0 myristoylation is essential for 
production of infectious RV virus, as previously observed for poliovirus8. We 
generated a RV construct allowing the expression of the RV polyprotein with a 
Glycine at position 2 mutated to an Alanine (G2A) at the N-terminus to block VP0 N-
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myristoylation. As expected, this mutation prevented recovery of viable virus 
(Supplementary Fig. 11), consistent with the hypothesis that VP0 myristoylation is 
required for formation of infectious virus particles. 
NMT inhibition prevents assembly of intact virions  
We next sought to determine the mechanism of antiviral activity. Interestingly, even 
though no new infectious virions are produced under NMT inhibition (Fig. 5a), IMP-
1088 blocked neither production of viral RNA (Fig. 5b), nor translation of rhinovirus 
polyprotein (Fig. 5c and d), an outcome which was conserved in primary hBECs 
(Supplementary Fig. 12). These data suggest that the key step mediating NMT 
inhibitor efficacy lies between protein translation and production of infectious virions. 
Since processing of viral polyprotein appeared to be unaffected (Fig. 5c), we 
investigated the effect of IMP-1088 on virus assembly itself by fractionating cell 
lysates from infected cells on a sucrose density gradient to separate viral assembly 
intermediates, and analyzing fractions by Western blotting with an anti-rhinovirus 
capsid antibody. In DMSO-treated controls capsid proteins were detected in intact 
virion and empty capsid fractions; the latter represent capsids which have formed 
without packaging the RNA genome, and are commonly observed in cells containing 
rapidly replicating virus. However, in IMP-1088 treated cell lysates, capsid proteins 
were detected predominantly in unassembled monomer/pentamer fractions (Figs. 5e 
and 5f), whilst assembled virions were essentially undetectable, indicating that IMP-
1088 blocks virus assembly. Western blot analysis of cell lysates from infected cells 
revealed a marked decrease in the amount of VP2 protein detected under NMT 
inhibition, while the total amount of other capsid proteins remained similar 
(Supplementary Fig. 13). Since the maturation cleavage of VP0 to generate VP4 and 
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VP2 only occurs in fully assembled particles25, the absence of VP2 further supports 
the conclusion that NMT inhibition blocks the assembly of infectious virus.  
Discussion 
The results described here establish a new series of human NMT inhibitors, 
discovered through an unusual fragment reconstruction approach starting from two 
very weak HsNMT inhibitors identified in high-throughput screens against 
heterologous parasite targets. By leveraging crystallographic binding modes 
determined in the parasite NMTs we constructed fragment-like compounds with 
remarkable cooperative inhibitory effects, and complementary binding modes as 
revealed in the structure of a quaternary complex of both fragments with HsNMT1 
and a co-substrate analogue. The perfectly poised binding modes of these fragments 
enabled rapid fragment linking optimization guided by crystallography at each step, 
firstly by improving a key H-bond acceptor, and subsequently controlling linker 
conformation to deliver IMP-1088, an exceptionally potent HsNMT1/2 dual inhibitor. 
Although the enzyme inhibitory potency of IMP-1088 lies beyond the effective range 
of an enzyme activity assay, subsequent antiviral studies in cells and SPR studies 
together suggest an IC50 of approximately 200 pM for IMP-1088 against HsNMT1/2. 
We anticipate that IMP-1088 will be an excellent probe to enable future studies of the 
role of NMT and N-myristoylation in human cell and disease biology, as exemplified 
by the work reported here on picornaviral replication. 
Multiple lines of evidence support the hypothesis that IMP-1088 effectively and 
potently inhibits production of infectious rhinovirus virions by blocking rhinovirus VP0 
N-myristoylation. Using a powerful chemical tagging approach in cells infected with 
RV, we demonstrate a specific impact of IMP-1088 on de novo N-myristoylation of 
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NMT substrate proteins with no impact on protein synthesis, confirming selective 
target engagement by IMP-1088. This chemical proteomic analysis also provides the 
first direct evidence for N-myristoylation of RV VP0, confirming it as a substrate of 
host NMT. We used IMP-1088 as a chemical probe to demonstrate the critical role of 
VP0 myristoylation in virion assembly, particularly in the transition to intact capsids, 
suggesting that the myristate group is important for aggregation of protomers and 
pentamers. This hypothesis is in line with genetic studies in poliovirus8-11, and is fully 
consistent with the results reported here on an RV VP0 mutant, further supporting 
the selectivity of IMP-1088 and providing the first unambiguous pharmacological 
evidence for NMT as a highly effective antipicornaviral target. 
In keeping with its specific mode of action, NMT inhibition has no impact on viral 
RNA replication or polyprotein synthesis, nor does it impact host cell viability over the 
course of infection. Indeed, thanks to its potent antiviral activity, IMP-1088 is highly 
effective in protecting host cells from the cytotoxic effects of viral infection. Previous 
studies of the role of NMT in cancer cell lines13,20 support the hypothesis that the 
large efficacy window between host and virus is a result of substantial differences in 
the rate of protein turnover. At the point of inhibitor treatment, pre-existing N-
myristoylated host proteins must be degraded before an impact on the cell is 
observed, a process which takes several days20 compared to a matter of hours for 
cytotoxicity driven by RV replication. Furthermore, we have shown that NMT activity 
recovers rapidly following inhibitor wash-out, with no long-term effects on cell 
viability. Together these data suggest that a substantial therapeutic window might 
exist for a drug targeting NMT in picornaviral infections, provided dosing is 
undertaken near the start of infection and does not extend beyond the few hours 
required to suppress replication. In the case of asthma, cystic fibrosis or COPD, we 
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suggest that this window might be expanded by inhaled delivery of an NMT inhibitor 
directly to the site of respiratory infection, and by tuning pharmacokinetics to limit 
systemic stability and thus prevent distribution of active inhibitor beyond the lung. 
Clearly, extensive toxicological studies will be required in future to determine 
whether the benefits of efficacy and novel mode of action outweigh the potential risks 
of targeting the host lipidation machinery. Intervention in RV infection would also 
need to be coupled to diagnosis in the earliest hours post-infection, methods for 
which are currently lacking in the clinic. The observation that many picornaviruses 
have evolved to depend on host myristoylation suggests that this mode of action 
might circumvent the development of resistance to a drug targeting NMT, since viral 
mutations would not influence inhibitor potency against a host enzyme. Interestingly, 
the concept of targeting a core host lipidation process to block viral replication was 
recently validated in the clinic in a phase 2A trial of an inhibitor of host prenylation of 
Hepatitis D virus26. 
Our data show that pharmacological NMT inhibition effects complete inhibition of RV 
replication in both multi-cycle and single-cycle infection assays, across a number of 
RV serotypes, in HeLa cells and in primary cells, in the presence of a standard of 
care corticosteroid for asthma and COPD, and in poliovirus and FMDV infections. RV 
is the most common respiratory virus associated with pulmonary exacerbations and 
morbidity in asthma and COPD, and in cystic fibrosis, where patients have a high 
virus burden in the lungs which is associated with a worsening of their condition. The 
data presented here suggest that human NMT merits further investigation as a drug 
target in myristoylation-dependent picornavirus infections, with potential applications 
in the treatment of RV-induced exacerbations of asthma, COPD, cystic fibrosis, and 
other picornaviral diseases.  
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Methods 
Details for the synthesis and characterization of all compounds, crystallography, 
biochemistry, cell biology and virology, protein labeling and proteomics are provided 
in Supplementary Information. 
Data Availability Statement 
All relevant data are available from the authors, and 3D structure coordinates and 
proteomics datasets have been deposited to public repositories, as detailed below. 
Accession codes 
Primary accessions (Protein Data Bank): 5MU6 (Hs:MYA:IMP-1088); 5O48 
(Pv:NHM:IMP-72); 5O4V (Pv:NHM:IMP-72+IMP-358); 5O6H (Hs:MYA:IMP-917); and 
5O6J (Hs:MYA:IMP-1031). 
The mass spectrometry proteomics data have been deposited to the 
ProteomeXchange Consortium (http://proteomecentral.proteomexchange.org) via the 
PRIDE partner repository27 with the dataset identifier PXD005798. 
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Figure 1: Proposed pathway for generation of infectious rhinovirus particles in 
an infected host cell.  (a) Rhinovirus polyprotein is synthesized in the host, where it 
undergoes co-translational N-terminal methionine excision by host methionine 
aminopeptidase (MetAP) to reveal an N-terminal glycine, followed by N-terminal N-
myristoylation by host NMT. (b) Capsid assembly starts with cleavage into VP0, VP3 
and VP1 by RV protease, and assembly into protomers; protomers then assemble 
into pentamers, and then into an icosahedral capsid enclosing the RV RNA genome; 
finally, VP0 is processed into VP4 and VP2, and mature infectious virions are 
released.  
 
Figure 2: Structure-guided discovery of potent human N-myristoyltransferase 
inhibitors. (a) Structures of hit compound IMP-72 and methylated analogue IMP-
994, reconstructed fragment IMP-358 and fragment-linked compound IMP-917, and 
associated inhibitory activity (IC50) on human NMT1 (HsNMT1). (b) Binding mode of 
IMP-72 in Plasmodium vivax NMT (PvNMT) determined to 1.69 Å resolution, in the 
presence of NHM (PDB: 5O48). Atoms colored by element: oxygen, red; nitrogen, 
blue; carbon, ice blue (inhibitor) and grey (protein); fluorine, purple. NHM, protein 
main chain and solvent molecules have been omitted for clarity, and polar protein-
inhibitor interactions are shown by dashed lines. (c) Quaternary complex of PvNMT, 
NHM, IMP-72 and IMP-358 (PDB: 5O4V) determined to 1.7 Å resolution, with IMP-
358 colored in lemon. (d)  Binding sites for NHM, IMP-72 and IMP-358, in the 
context of the overall structure of PvNMT. The protein is a ribbon color-ramped from 
the N-terminus (blue) to the C-terminus (red). NHM, IMP-72 and IMP-358 are shown 
in space-filling representation colored by atom type (phosphorus, magenta) and 
distinguished by carbon atoms shown in grey, ice-blue and lemon, respectively. 
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(e) Binding mode of IMP-917 in human NMT1 (HsNMT1) with Myr-CoA (PDB 5O6H) 
determined to 1.29 Å resolution. Carbon atoms of the IMP-917 indazole core are 
colored ice blue, while those of the pendant trimethylpyrazole-containing species are 
lemon. See Supplementary Fig. 1 for ligand electron density maps. 
 
Figure 3: Potent inhibitors of human N-myristoyltransferases inhibit rhinovirus 
myristoylation in infected cells. (a) Structures of IMP-1088 and IMP-1031, and in 
vitro inhibitory activity (IC50) on human NMT1 (HsNMT1) and NMT2 (HsNMT2). (b) 
Binding mode of IMP-1088 in the ternary complex with human NMT1 and Myr-CoA 
(PDB: 5MU6), determined to 1.88 Å resolution, colored as in Fig. 2e. (c) Analysis of 
protein myristoylation in HeLa cells infected with rhinovirus RV-A16 (MOI 20) in 
presence of YnMyr, following ligation to TAMRA/Biotin azido capture reagent AzTB; 
red arrow: band of increased fluorescence intensity upon infection, corresponding to 
VP0. (d) Quantitative proteomic analysis of inhibition of protein myristoylation in RV-
A16-infected HeLa cells (6 hours) by IMP-1088, following ligation to AzRB and 
enrichment on NeutrAvidin-agarose beads. Two-sample t-test (permutation-based 
false discovery rate (FDR), 250 permutations, FDR 0.01, S0=0.5) revealed 
significant changes in label-free quantification (LFQ) between 50 nM IMP-1088 and 
control (DMSO) for myristoylated proteins. Dashed lines: t-test significance cut off; 
red: RV-A16 proteins; blue: known co-translationally myristoylated host proteins13; 
white: other host proteins. Similar analyses were performed for the whole proteome 
(see Supplementary Fig. 3). (e) Western blot and in-gel fluorescence analysis of 
inhibition of VP0 myristoylation in HeLa cells infected with rhinovirus RV-A16 (MOI 
20, 6 h) following recovery ligation to AzTB. Comparison of input protein, 
supernatant following pull-down on Streptavidin magnetic beads (Supnt) and eluted 
22 
 
proteins (Pull-down) demonstrates enrichment of YnMyr-tagged VP0, and specific 
inhibition of myristoylation; HSP90: non-myristoylated loading control.  
 
Figure 4: Novel human N-myristoyltransferase inhibitors potently and 
efficiently block rhinovirus replication without cytotoxicity. (a) Multicycle 
rhinovirus replication assay. HeLa cells were infected with rhinovirus RV-A16 (MOI 
0.5) for 2 days, and virus replication measured by the induced cytopathic effect 
(%CPE) for each inhibitor relative to vehicle (DMSO)-treated infected control, and 
uninfected controls. Error bars: SEM, n=3. (b) Cell viability in presence of NMT 
inhibitors for uninfected HeLa cells, as percentage of vehicle-treated control. Error 
bars: SEM, n=3. (c) and (d) Inhibition of single cycle replication in HeLa cells 
infected with rhinovirus RV-A16 (MOI 20) (c), or the indicated rhinovirus serotypes 
(d), for 6 h with indicated concentrations of IMP-1088; virus titers determined by 
endpoint dilution assay. TCID50: 50% Tissue Culture Infective Dose, error bars: SEM, 
n=4 for (c) and n=3 for (d), ****: p<0.0001 (two-way ANOVA with Sidak's multiple 
comparisons test on log10(TCID50/ml)). (e) Inhibition of single cycle replication in 
primary human bronchial epithelial cells (hBECs) infected with rhinovirus RV-A1 
(MOI 5) for 7 h by IMP-1088; virus titers determined as in (c)/(d). Error bars: SEM, 
n=4. (f) Inhibitory effect of IMP-1088 added at different times post-infection, in a 
single cycle replication assay. HeLa cells were infected with rhinovirus RV-A16 (MOI 
20) for 6 h and IMP-1088 (500 nM) added at the indicated times (+/- hours) relative 
to the time point of virus adsorption. Error bars: SEM, n=3, **: p=0.0013, 
****: p<0.0001 (one-way ANOVA with Dunnett's multiple comparisons test on 
log10(TCID50/ml) against the DMSO control). 
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Figure 5: IMP-1088 inhibits production of infectious rhinovirus particles by 
blocking virus assembly. (a-d) Effect of IMP-1088 on rhinovirus replication kinetics 
in HeLa cells infected with rhinovirus RV-A16 (MOI 20) for 6 h in presence of IMP-
1088 (500 nM) or DMSO (vehicle). At the indicated time points cell, lysates were 
analyzed for virus titer by endpoint titration (a), viral RNA by quantitative PCR (b) or 
viral protein levels by Western blot with an antibody directed against rhinovirus non-
structural protein 2C ((c) and (d)). (c) Representative images of one of three 
independent repeats. (d) Quantification of signal corresponding to 2C protein, 
relative to Lamin B1 loading control, expressed as a percentage of 6 h DMSO 
control. Error bars: SEM, n=3. (e) Effect of IMP-1088 on rhinovirus capsid assembly. 
HeLa cells were infected with rhinovirus RV-A16 for 6 h in presence of IMP-1088 
(500 nM) or DMSO (vehicle). Cell lysates were sedimented on sucrose density 
gradients and the fractions analyzed by Western blot with antibodies raised against 
whole rhinovirus RV-A16 capsids. (f) Densitometric analysis of (e), with indication of 
fractions in which controls sedimented (intact virion, empty capsid or 
monomer/pentamer). 
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